Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Bria

Showing results (41-50 of 416) with videos related to

Pageof 42
Sort By:
Clinical Lung Cancer|May 25, 2019
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case ReportGiacomo Bertelli, Rosalinda Trovato, Stefano Ugel, et al.
Critical Reviews in Oncology/Hematology|August 31, 2015
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancerFrancesca Maines, Orazio Caffo, Antonello Veccia, et al.
The Oncologist|March 20, 2025
Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case reportAntonio Vitale, Emanuele Vita, Alessio Stefani, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2020
Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitorsRoberto Iacovelli, Chiara Ciccarese, Emilio Bria, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy numberSara Pilotto, Emilio Bria, Umberto Peretti, et al.
Nutrients|April 23, 2022
Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary ApproachesChiara Cencioni, Ilaria Trestini, Geny Piro, et al.
Expert Opinion on Biological Therapy|July 21, 2015
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectivesLorenzo Calvetti, Sara Pilotto, Luisa Carbognin, et al.
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|June 23, 2004
[Metastatic breast cancer: is global survival increase a realistic endpoint in phase III clinical trials? Studies on taxanes; studies on trastuzumab]Emilio Bria, Barbara Vanni, Federica Cuppone, et al.
Expert Review of Molecular Diagnostics|October 17, 2017
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune systemGiulia Grizzi, Mario Caccese, Anastasios Gkountakos, et al.
European Urology|July 13, 2006
Adjuvant chemotherapy for bladder cancer: the chance for meta-analyses comparisonEmilio Bria, Enzo Maria Ruggeri, Camillo Francesco Pollera, et al.
Pageof 42

Showing results (41-50 of 416) with videos related to

Sort By:
Pageof 42
Clinical Lung Cancer|May 25, 2019
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case ReportGiacomo Bertelli, Rosalinda Trovato, Stefano Ugel, et al.
Critical Reviews in Oncology/Hematology|August 31, 2015
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancerFrancesca Maines, Orazio Caffo, Antonello Veccia, et al.
The Oncologist|March 20, 2025
Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case reportAntonio Vitale, Emanuele Vita, Alessio Stefani, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2020
Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitorsRoberto Iacovelli, Chiara Ciccarese, Emilio Bria, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy numberSara Pilotto, Emilio Bria, Umberto Peretti, et al.
Nutrients|April 23, 2022
Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary ApproachesChiara Cencioni, Ilaria Trestini, Geny Piro, et al.
Expert Opinion on Biological Therapy|July 21, 2015
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectivesLorenzo Calvetti, Sara Pilotto, Luisa Carbognin, et al.
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|June 23, 2004
[Metastatic breast cancer: is global survival increase a realistic endpoint in phase III clinical trials? Studies on taxanes; studies on trastuzumab]Emilio Bria, Barbara Vanni, Federica Cuppone, et al.
Expert Review of Molecular Diagnostics|October 17, 2017
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune systemGiulia Grizzi, Mario Caccese, Anastasios Gkountakos, et al.
European Urology|July 13, 2006
Adjuvant chemotherapy for bladder cancer: the chance for meta-analyses comparisonEmilio Bria, Enzo Maria Ruggeri, Camillo Francesco Pollera, et al.
Pageof 42